SU2C Scientific Research Teams

Share this:

Like this page on Facebook

Peter A. Jones, Ph.D., D.Sc.

Scientific Research Team:
Bringing Epigenetic Therapy to the Forefront of Cancer Management

Peter A. Jones, Ph.D., D.Sc.

Peter A. Jones, Ph.D., D.Sc., is director of the University of Southern California/Norris Comprehensive Cancer Center, director of the Urological Research Laboratories and distinguished professor of biochemistry and molecular biology and urology at the Keck School of Medicine of University of Southern California. Jones also holds the H. Leslie and Elaine S. Hoffman cancer research chair at the University of Southern California.

Born, raised and educated in the former Rhodesia (now Zimbabwe), Jones received his doctorate in biochemistry from the University of London in 1973. He joined the University of Southern California in 1977, where he attained the rank of professor in 1985 and became director of the cancer center in 1993.

Jones’ research concerns how cancer-related genes become heritably silenced during carcinogenesis, resulting in functional inactivation. The primary focus of his research is on DNA cytosine methylation and how this process interacts with chromatin structure to ensure heritable silencing. He is also interested in translating basic scientific discoveries into clinical treatments, specifically for people with bladder cancer. He and his colleagues are working on drugs that can reverse silencing and turn genes back on again, and designing strategies where this kind of epigenetic therapy can be applied to the treatment of human cancers.

A past president of the AACR and deputy editor of Cancer Research, Jones is the author of more than 250 journal publications and book chapters and serves on several national and international committees, panels and editorial boards. He has received a variety of honors, including the University of Southern California Associates Award for Creativity in Research and Scholarship and the Outstanding Investigator Grant from the National Cancer Institute. Recently, Jones, along with his colleague Stephen B. Baylin, M.D, deputy director of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, received the Kirk A. Landon-AACR Prize for Basic and Translational Cancer Research.

Here we stand on the verge of unlocking the secrets that will end cancer. Donate Now.
A one percent reduction in cancer deaths would be worth $500 billion, almost 2.5 times what the U.S. spends each year on the disease.